Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa

J Am Acad Dermatol. 2020 Nov;83(5):1441-1444. doi: 10.1016/j.jaad.2020.06.042. Epub 2020 Jun 18.

Authors

Thomas Bettuzzi¹, Laure Frumholtz¹, Marie Jachiet¹, Clémence Lepelletier¹, Mourad Djermane¹, Florence Cordoliani¹, Anne Saussine¹, Jean-David Bouaziz¹, Hervé Bachelez²

Affiliations

¹ Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
² Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, Paris, France; Laboratory of Genetics of Skin Diseases, Unité Mixte de Recherche (UMR) Inserm U1163, Institut Imagine, Paris, France. Electronic address: herve.bachelez@aphp.fr.

PMID: 32565204
DOI: 10.1016/j.jaad.2020.06.042

No abstract available

Publication types

Letter

MeSH terms

Adult
Drug Combinations
Female
Hidradenitis Suppurativa / drug therapy*
Humans
Male
Retrospective Studies
Severity of Illness Index
Sirolimus / administration & dosage*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Drug Combinations
Tumor Necrosis Factor-alpha
Sirolimus